Recent Updates
Recently added Catalysts
IRWD Positive Sentiment

Ironwood Pharmaceuticals to Host Third Quarter 2026 Investor Update Call

Wednesday, October 28, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Ironwood Pharmaceuticals announced it will host its third quarter 2026 investor update call on November 5, 2026, at 8:30 a.m. ET. Participants can join by dialing specific phone numbers or accessing the webcast through the company's website. This event aims to provide updates to investors.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ironwood Pharmaceuticals is hosting an investor update call.
  • The call is scheduled for November 5, 2026.
  • Investors can participate via phone or webcast.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+57%
120-day peak, hindsight
Typical move
3.8%
average across 2 past catalysts
Lead asset
Apraglutide
Phase 1 · Hepatic Impairment

Full Press Release Details

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its third quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 5, 2026. Individuals interested in participating in the call should dial (833) 461-5787 (U.S.) or (585) 542-9983 (international) using conference ID number and event passcode 496523279. To access the webcast, please visit the Investors & Media section of Ironwood’s website at ww

Frequently Asked Questions

When is the Ironwood investor update call scheduled?

The call is scheduled for November 5, 2026, at 8:30 a.m. ET.

How can I participate in the investor call?

Participants can dial specific phone numbers or access the webcast online.

What is the conference ID for the call?

The conference ID number is 496523279.

Where can I find the webcast link?

The webcast link is available in the Investors & Media section of Ironwood's website.

ShareAdd on Google
Tags: IRWD Ironwood Pharmaceuticals investor update Q3 2026 conference call webcast
Last updated: Oct 28, 2026

Biotech snapshot

Cash runway
$79M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ApraglutidePhase 1
Hepatic Impairment →

Catalyst track record

+57%
best trade around IRWD's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for IRWD.

See every catalyst's timing & PoA →